Fortress Biotech Inc. [NASDAQ: FBIO] loss -9.56% or -0.43 points to close at $4.07 with a heavy trading volume of 1234682 shares. The company report on April 21, 2021 that Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit.
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating ’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, announced that Manuel Litchman, M.D., President and Chief Executive Officer, and Knut Niss, Ph.D., Chief Technology Officer, will participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit, taking place virtually on April 26 and 27, 2021. The company will participate in a fireside chat on Monday, April 26, 2021, at 3:15 p.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company’s fireside chat will be available on the Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.
About Mustang BioMustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating ’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.
It opened the trading session at $4.44, the shares rose to $4.45 and dropped to $4.02, the range by which the price of stock traded the whole day. The daily chart for FBIO points out that the company has recorded 85.00% gains over the past six months. However, it is still -103.5% lower than its most recent low trading price.
If we look at the average trading volume of 1.99M shares, FBIO reached to a volume of 1234682 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Fortress Biotech Inc. [FBIO]:
The Benchmark Company have made an estimate for Fortress Biotech Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 02, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on December 18, 2019, representing the official price target for Fortress Biotech Inc. stock. Previously, the target price had yet another raise to $10, while B. Riley FBR Inc. analysts kept a Buy rating on FBIO stock.
The Average True Range (ATR) for Fortress Biotech Inc. is set at 0.39, with the Price to Sales ratio for FBIO stock in the period of the last 12 months amounting to 8.51. The Price to Book ratio for the last quarter was 3.23.
Trading performance analysis for FBIO stock
Fortress Biotech Inc. [FBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.22. With this latest performance, FBIO shares dropped by -2.63% in over the last four-week period, additionally plugging by 85.00% over the last 6 months – not to mention a rise of 94.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FBIO stock in for the last two-week period is set at 45.69, with the RSI for the last a single of trading hit 41.37, and the three-weeks RSI is set at 48.00 for Fortress Biotech Inc. [FBIO]. The present Moving Average for the last 50 days of trading for this stock 4.18, while it was recorded at 4.31 for the last single week of trading, and 3.50 for the last 200 days.
Fortress Biotech Inc. [FBIO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Fortress Biotech Inc. [FBIO] shares currently have an operating margin of -206.74 and a Gross Margin at +62.99. Fortress Biotech Inc.’s Net Margin is presently recorded at -102.03.
Return on Total Capital for FBIO is now -40.68, given the latest momentum, and Return on Invested Capital for the company is -30.05. Return on Equity for this stock declined to -73.53, with Return on Assets sitting at -16.76. When it comes to the capital structure of this company, Fortress Biotech Inc. [FBIO] has a Total Debt to Total Equity ratio set at 83.49. Additionally, FBIO Total Debt to Total Capital is recorded at 45.50, with Total Debt to Total Assets ending up at 25.48. Long-Term Debt to Equity for the company is recorded at 81.65, with the Long-Term Debt to Total Capital now at 44.50.
Reflecting on the efficiency of the workforce at the company, Fortress Biotech Inc. [FBIO] managed to generate an average of -$419,153 per employee. Receivables Turnover for the company is 2.64 with a Total Asset Turnover recorded at a value of 0.16.Fortress Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.50.
Fortress Biotech Inc. [FBIO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Fortress Biotech Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FBIO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Fortress Biotech Inc. go to 25.50%.
An analysis of insider ownership at Fortress Biotech Inc. [FBIO]
There are presently around $144 million, or 34.60% of FBIO stock, in the hands of institutional investors. The top three institutional holders of FBIO stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 8,680,909, which is approximately 5.544% of the company’s market cap and around 26.90% of the total institutional ownership; BLACKROCK INC., holding 4,719,280 shares of the stock with an approximate value of $21.24 million in FBIO stocks shares; and VANGUARD GROUP INC, currently with $20.56 million in FBIO stock with ownership of nearly 39.64% of the company’s market capitalization.
Positions in Fortress Biotech Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 47 institutional holders increased their position in Fortress Biotech Inc. [NASDAQ:FBIO] by around 3,361,140 shares. Additionally, 33 investors decreased positions by around 2,159,473 shares, while 17 investors held positions by with 26,526,922 shares. The mentioned changes placed institutional holdings at 32,047,535 shares, according to the latest SEC report filing. FBIO stock had 19 new institutional investments in for a total of 835,141 shares, while 9 institutional investors sold positions of 158,911 shares during the same period.